Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David C Norris

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
JAMA|January 17, 2014
Financial incentives to control hypertension in patientsDavid C Norris
Drug Discovery Today|November 25, 2017
One-size-fits-all dosing in oncology wastes money, innovation and livesDavid C Norris
CPT: Pharmacometrics & Systems Pharmacology|September 5, 2023
How large must a dose-optimization trial be?David C Norris
JAMA Pediatrics|April 23, 2019
Ethical Review and Methodologic Innovation in Phase 1 Cancer TrialsDavid C Norris
Health Affairs (Project Hope)|October 9, 2013
Racial disparities in hospital selectionDavid C Norris
JAMA|July 10, 2014
Housing mobility and adolescent mental healthDavid C Norris
Journal of Evaluation in Clinical Practice|January 28, 2017
Casting a realist's eye on the real world of medicine: Against Anjum's ontological relativismDavid C Norris
F1000Research|August 8, 2017
Dose Titration Algorithm Tuning (DTAT) should supersede 'the' Maximum Tolerated Dose (MTD) in oncology dose-finding trialsDavid C Norris
Journal of General Internal Medicine|April 5, 2013
Community-acquired pneumonia and proton pump inhibitorsDavid C Norris
Health Affairs (Project Hope)|September 10, 2014
No credible alternative to 'the basic flaw'David C Norris
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
JAMA|January 17, 2014
Financial incentives to control hypertension in patientsDavid C Norris
Drug Discovery Today|November 25, 2017
One-size-fits-all dosing in oncology wastes money, innovation and livesDavid C Norris
CPT: Pharmacometrics & Systems Pharmacology|September 5, 2023
How large must a dose-optimization trial be?David C Norris
JAMA Pediatrics|April 23, 2019
Ethical Review and Methodologic Innovation in Phase 1 Cancer TrialsDavid C Norris
Health Affairs (Project Hope)|October 9, 2013
Racial disparities in hospital selectionDavid C Norris
JAMA|July 10, 2014
Housing mobility and adolescent mental healthDavid C Norris
Journal of Evaluation in Clinical Practice|January 28, 2017
Casting a realist's eye on the real world of medicine: Against Anjum's ontological relativismDavid C Norris
F1000Research|August 8, 2017
Dose Titration Algorithm Tuning (DTAT) should supersede 'the' Maximum Tolerated Dose (MTD) in oncology dose-finding trialsDavid C Norris
Journal of General Internal Medicine|April 5, 2013
Community-acquired pneumonia and proton pump inhibitorsDavid C Norris
Health Affairs (Project Hope)|September 10, 2014
No credible alternative to 'the basic flaw'David C Norris
Pageof 2